Despite what the name suggests, Polyendocrine Metabolic Ovarian Syndrome isn’t just about ovaries—or cysts, for that matter. In fact, many people diagnosed with PMOS don’t have any ovarian cysts at all. Confusing? You’re not alone. The name dates back to how the condition was first described, but science has come a long way since then. Today, we understand that PCOS is really a complex hormonal and metabolic condition that affects far more than reproductive health.
At its core, PMOS is about hormonal imbalance. When key hormones like insulin, androgens (like testosterone), and others are out of sync, they can create a domino effect throughout the body. This hormonal miscommunication can lead to irregular periods, acne, weight changes, hair loss or excess hair growth, difficulty with ovulation or fertility—and that’s just the shortlist. But here’s the thing: PMOS doesn’t follow a single pattern. Some women experience textbook symptoms. Others don’t fit the mold at all. That’s part of what makes PMOS so challenging—and why understanding your unique experience matters.
So, how can the PMOS Association help?
We’re here to offer more than definitions. We’re here to offer direction. Whether you’re newly diagnosed, still searching for answers, or years into your journey and feeling stuck, we’re committed to helping you make sense of PMOS—and make progress.
Here’s what you’ll find at PMOSA:
✅ Reliable, science-backed information about what PMOS is (and isn’t)
💬 Supportive communities of people who understand exactly what you’re going through
🧬 Resources for navigating fertility, metabolic health, nutrition, and more
🧠 Education for providers who want to better support their PMOS patients
🙋♀️ Advocacy to make sure PMOS is recognized, researched, and respected
No fluff. No fad cures. Just real support, grounded in evidence and compassion.
At PMOSA, we believe every person with PCOS deserves to be informed, empowered, and heard. Wherever you are in your journey, we’re honored to walk with you.
pcos: Latest results from PubMed
CONCLUSION: This study provides an exploratory view of PCOS-related symptom patterns, diagnostic pathways, and treatment behaviors among a predominantly young convenience sample of Iraqi women. Given the sampling strategy and reliance on self-reported information, the findings should be interpreted cautiously as hypothesis-generating rather than nationally representative of Iraqi women. Nevertheless, the observed heterogeneity and fertility-related concerns may help inform culturally sensitive...
Published on: Wed, 04 Nov 2026 06:00:00 -0500
Authors: H Oufi, R Kutaif, R Alabd, H Abd, R Hameed, E Al-Muhanna, D Abd, R Yousif,
CONCLUSION: In patients with PCOS, dyslipidemia is closely associated with reproductive hormone imbalances and menstrual irregularity. TG and HDL-C levels were independently associated with menstrual regularity. Dyslipidemia is not only a metabolic abnormality but may also contribute to the development of the endocrine phenotype of PCOS. Clinical management should consider the potential value of lipid-targeted interventions in improving reproductive and menstrual outcomes.
Published on: Wed, 04 Nov 2026 06:00:00 -0500
Authors: Xinyi Shi, Yanyu Zhong, Qing Zhao, Xuanping Lu, Yanping Pan,
CONCLUSION: An imbalance between oxidative and antioxidative systems is associated with female infertility. TAC demonstrated the highest discriminative ability and may represent a useful noninvasive biomarker of infertility-associated OS.
Published on: Wed, 04 Nov 2026 06:00:00 -0500
Authors: Faegheh Bahri, Mohammad Erfan Norouzmahani, Mojgan Moshrefi, Sina Habibi, Iman Rad, Gholamreza Asadikaram, Sanaz Faramarz, Danial Abdollahdokht, Victoria Habibzadeh, Shirin Orandi, Mohammad Hadi Nematollahi,
Extracellular vesicles (EVs) carry proteins, lipids and nucleic acids that can influence ovarian and systemic metabolic function. This narrative review examines their molecular mechanisms, biomarker potential and experimental therapeutic applications in polyendocrine metabolic ovarian syndrome (PMOS), previously termed polycystic ovary syndrome. Follicular fluid EV cargo varies with disease phenotype and adiposity, but these associations have not established clinically validated diagnostic...
Published on: Wed, 04 Nov 2026 06:00:00 -0500
Authors: Lijing Qi, Yue Jiang, Yanhua Han, Cong Feng, Liyan Jia, Yuehui Zhang,
CONCLUSION: The study suggests that serum AMH is relevant for the diagnosis of PCOS. Based on the findings, we propose a serum AMH cutoff value of 3.41 ng/mL for the diagnosis of PCOS in Tunisian hyperandrogenic adult women.
Published on: Wed, 04 Nov 2026 06:00:00 -0500
Authors: Marwa Chiboub, Marouen Braham, Radhouane Gharbi, Marwa Bennour, Nozha Chakroun, Manel Hamdoun-Zahmoul, Moncef Feki, Manel Jemel, Ines Kammoun,
INTRODUCTION: Polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS), is a complex metabolic-reproductive disorder managed with lifestyle interventions, metformin, and symptom-directed therapies. Incretin-based therapies offer substantial metabolic benefits, but their reproductive efficacy, durability, and phenotypic safety remain incompletely defined.
Published on: Wed, 04 Nov 2026 06:00:00 -0500
Authors: Basak Ozgen Saydam, Bulent Okan Yıldız,
Polycystic ovary syndrome (PCOS) is a complex endocrine and metabolic disorder affecting women of reproductive age. It is commonly associated with insulin resistance, hyperandrogenism, chronic low-grade inflammation, and oxidative stress. These factors contribute to metabolic dysfunction and increase the risk of developing type 2 diabetes and cardiovascular complications. This narrative review critically evaluates the available evidence regarding nutraceutical and herbal interventions targeting...
Published on: Tue, 03 Nov 2026 06:00:00 -0500
Authors: Sayantan Kundu, Riya Jana, Monosiz Rahaman, Sourav Ghosh,
CONCLUSION: A1 significantly restored endocrine and hormonal markers, glucose, insulin, and dyslipidemia while enhancing FSHR gene expression; molecular docking predicted binding within the FSHR allosteric pocket, a finding not yet functionally validated. These results indicate that A1, a novel 7-azaindole derivative, may regulate reproductive and metabolic dysfunctions in PCOS through endocrine modulation and receptor-- mediated mechanisms, demonstrating significant therapeutic potential for...
Published on: Tue, 03 Nov 2026 06:00:00 -0500
Authors: Maryam Mehmood, Sadaf Naeem, Sajda Ashraf, Anosh Tahir, Shazia Haider, Faheema Siddiqui, Zafar Saied Saify, Saira Saeed Khan,
CONCLUSIONS: Circulating alarin is closely associated with the metabolic and reproductive features of PCOS rather than psychiatric symptom severity, indicating a stronger link to endocrine-metabolic dysregulation.
Published on: Tue, 03 Nov 2026 06:00:00 -0500
Authors: Hend Abd Elhamed, Olfat Fawzy, Doaa Sayed, Shaimaa Younes Abd Elaziz, Hager Abdelgawad, Emad Gamil Khidr,
ObjectiveTo investigate whether early-pregnancy insulin resistance in women with polycystic ovary syndrome (PCOS) is associated with adverse maternal pregnancy complications and neonatal/perinatal outcomes after adjustment for common metabolic confounders.MethodsThis retrospective cohort study included 168 pregnant women diagnosed with PCOS who were consecutively enrolled at Tongren Hospital from July 2023 to December 2024. Of these, 52 patients with insulin resistance (homeostasis model...
Published on: Mon, 02 Nov 2026 06:00:00 -0500
Authors: Zhifen Hua, Liping Shen, Wei-Na Chen,
Polycystic ovary syndrome (PCOS) is a prevalent and complex hormone-metabolic condition that impacts females of reproductive age. Current pharmacological treatments often address limited symptoms, may involve long-term use of synthetic drugs, and are frequently associated with adverse effects and limited patient adherence. In recent years, natural therapeutic agents such as Lutein and Myo-inositol have acquired increasing interest due to their promising biological properties and minimal side...
Published on: Mon, 02 Nov 2026 06:00:00 -0500
Authors: Snigdha Bhardwaj, Nikita Sharma, Khushi Sharma, Kandasamy Nagarajan,
No abstract
Published on: Mon, 02 Nov 2026 06:00:00 -0500
Authors: Hefziba Lorences-Noguera, Esteban Cardenas-Duran,
No abstract
Published on: Mon, 02 Nov 2026 06:00:00 -0500
Authors: Jixiang Pei, Chao Huang, Kuo Wang, Junjie Guo,
Polycystic ovary syndrome (PCOS) is a prevalent endocrine and reproductive disorder in women of childbearing age. Chronic inflammatory status is common among PCOS patients, and numerous studies have verified that this population exhibits dysregulated inflammatory cytokines and immune cell imbalance. Such inflammatory disorders are characterized by aberrant expression of pro-inflammatory cytokines, inflammasomes and inflammatory markers. These abnormalities not only impair the female reproductive...
Published on: Mon, 02 Nov 2026 06:00:00 -0500
Authors: Liqian Zhang, Yue Gao, Ruirui Fan, Baichao Shi, Xiaoke Wu,
CONCLUSIONS: Aerobic exercise reduces androgen-related markers and luteinising hormone levels and increases sex hormone-binding globulin and follicle-stimulating hormone in women with PMOS, with no significant effects on the follicle-stimulating hormone/luteinising hormone ratio or anti-Müllerian hormone. Age, control type, and exercise modality may moderate intervention effects, and cycling showed potential advantages. However, the number of relevant studies and the sample sizes were limited,...
Published on: Sun, 01 Nov 2026 06:00:00 -0500
Authors: Mingnan Zhuang, Zongnan Liu, Henghao Yan, Mingyue Yin, Yilin Zhang, Donglin Shi,